Role of NIB in connecting science to patients by assuring safe and quality anti diabetic products
In India burden of diabetes is increasing and expected to cross the 100 million mark by 2030. Therefore, the development of national policies for the prevention, treatment, and care of diabetes in line with the sustainable development of health care systems is the need of the hour. National Institute of Biologicals (NIB) responsibly assures and reviews the quality of Biological products to the end users by weeding out “Not-of-Standard-Quality” Biological Medicines from reaching Indian market, thereby safeguarding the Public Health by testing at our state-of-art-laboratory. NIB receives samples from various sources such as State Port offices, Central Drug Standard Control Organization (CDSCO), Stakeholders of biotherapeutic manufacturers, legal & global tender samples. They are tested by pharmacopoeial methods or manufacturer’s method for Key Quality Attributes (KQA). The heterogeneity of products involves human recombinant biotherapeutic Insulin, Insulin Analogues, and Peptides of nearly 20 different types eg. Biphasic Insulin, Glargine, Aspart, Exenatide, Liraglutide, etc. which have their global presence for the antidiabetic patient care. Testing for quality attributes such as Identification, Potency, Purity, Stability, Related Impurity and Safety parameters along with the physiochemical test is carried out to ensure the safety, quality, and effectiveness of the product. In addition, reference standards are also being developed at NIB which serves as the measurement standards and complements the written standards in India pharmacopeia. All the testing is carried out strictly adhering to the timelines so that the quality product is delivered to meet the ever-growing public health challenge
NIB maintains quality systems of ISO 17025 standards for continuous improvement, function as Central Drugs Laboratory(CDL). It focuses on a continuous supply of lifesaving biotherapeutics to ensure the success of the Non-Communicable Disease (NCD) programme for Diabetes.
2. Kumar KMP, Banshi S, Rao PV, Sarda A, Vishwanathan V, Kalra S , Sethi B, Shah N, Srikanta SSS, Jain SM, et al. “Type 1 diabetes: Awareness, management and challenges: Current scenario in India”. Indian Journal of Endocrinology and metabolism 2015, 19:S6-S8.
3. National Institute of Biologicals.www.nib.gov.in. Accessed on October 201 7
4. Insulin basics. American Diabetes Association website. Last edited 2015
5. Guidance document, Recombinant Products laboratory, NIB. 12 sept 2013 http://www.nib.gov.in/guidance_document/RPL_Guidance_Document-Revised_12Sep2013.pdf
6. Moorkens E. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium. “Strategies of players on the global biopharmaceutical market” GaBI: 2017; Sept . (http://gabionline.net/Biosimilars/Research/Strategies-of-players-on-the-global-biopharmaceutical-market).
7. Williams R L, Bristow A F, Hauck W W, Srinivasan V S ,Morris T, Atouf F, Ambrose M,Surendranath K V, Chakrabarty R and Menon K: “Role of public standards in the Safety and Efficacy of biologic Medicines”. AAPS Journal May 2014, Volume 16, , pp 516–521
Copyright©2017 SKIMS Soura